Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
Cabaletta Bio (Nasdaq: CABA), a clinical-stage biotechnology company developing curative targeted cell therapies for autoimmune diseases, announced its participation in Guggenheim's Inaugural Healthcare Innovation Conference. The company will engage in a fireside chat on Monday, November 11, 2024, at 10:00 a.m. ET in Boston, MA.
The presentation will be accessible through a live webcast on the News and Events section of Cabaletta's website, with replays available for 30 days following the event.
Cabaletta Bio (Nasdaq: CABA), un'azienda biotecnologica in fase clinica che sviluppa terapie cellulari mirate curative per le malattie autoimmuni, ha annunciato la sua partecipazione alla Conferenza Inaugurale sull'Innovazione Sanitaria di Guggenheim. L'azienda parteciperà a una chiacchierata informale lunedì 11 novembre 2024, alle 10:00 ET a Boston, MA.
La presentazione sarà accessibile tramite una trasmissione web dal vivo nella sezione Notizie ed Eventi del sito di Cabaletta, con repliche disponibili per 30 giorni dopo l'evento.
Cabaletta Bio (Nasdaq: CABA), una empresa biotecnológica en etapa clínica que desarrolla terapias celulares dirigidas curativas para enfermedades autoinmunes, anunció su participación en la Conferencia Inaugural de Innovación en Salud de Guggenheim. La empresa participará en una charla informal el lunes 11 de noviembre de 2024, a las 10:00 a.m. ET en Boston, MA.
La presentación estará disponible a través de una transmisión en vivo en la sección de Noticias y Eventos del sitio web de Cabaletta, con repeticiones disponibles durante 30 días después del evento.
카발레타 바이오 (Nasdaq: CABA)는 자가면역 질환을 위한 치료적 표적 세포 치료제를 개발하는 임상 단계의 생명공학 회사로, 구겐하임의 최초 의료 혁신 컨퍼런스에 참여한다고 발표했습니다. 회사는 2024년 11월 11일 월요일 오전 10시(ET)에 매사추세츠주 보스턴에서 진행되는 대담에 참석할 예정입니다.
발표는 카발레타 웹사이트의 뉴스 및 이벤트 섹션을 통해 라이브 웹캐스트로 시청 가능하며, 이벤트 후 30일간 다시 시청할 수 있습니다.
Cabaletta Bio (Nasdaq: CABA), une entreprise de biotechnologie en phase clinique développant des thérapies cellulaires ciblées curatives pour les maladies auto-immunes, a annoncé sa participation à la Conférence Inaugurale sur l'Innovation en Santé de Guggenheim. L'entreprise participera à une discussion informelle le lundi 11 novembre 2024, à 10h00 (ET) à Boston, MA.
La présentation sera accessible via un webinaire en direct dans la section Actualités et Événements du site de Cabaletta, avec des rediffusions disponibles pendant 30 jours après l'événement.
Cabaletta Bio (Nasdaq: CABA), ein biotechnologisches Unternehmen in der klinischen Phase, das kurative gezielte Zelltherapien für Autoimmunerkrankungen entwickelt, gab seine Teilnahme an der ersten Gesundheitsinnovationskonferenz von Guggenheim bekannt. Das Unternehmen wird am Montag, den 11. November 2024, um 10:00 Uhr ET in Boston, MA, an einem informellen Gespräch teilnehmen.
Die Präsentation wird über einen Live-Stream im Bereich Nachrichten und Veranstaltungen der Website von Cabaletta zugänglich sein, mit Wiederholungen, die 30 Tage nach der Veranstaltung verfügbar sind.
- None.
- None.
PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Monday, November 11, 2024, at 10:00 a.m. ET in Boston, MA.
A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical trials in myositis, systemic lupus erythematosus, systemic sclerosis, generalized myasthenia gravis and in the RESET-PV™ sub-study within the DesCAARTes™ clinical trial in pemphigus vulgaris, along with the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK-associated myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
William Gramig
Precision AQ
william.gramig@precisionaq.com
FAQ
When is Cabaletta Bio (CABA) presenting at Guggenheim's Healthcare Innovation Conference 2024?
How can I watch Cabaletta Bio's (CABA) presentation at the Guggenheim Healthcare Conference?
What type of therapies is Cabaletta Bio (CABA) developing?
